The relationship between high-sensitive C-reactive protein and pulse wave velocity in healthy Japanese men

Objective: To examine the relationship between inflammation and central arterial stiffness in a type 2 diabetes Asian cohort. Method: Central arterial stiffness was estimated by carotid-femoral pulse wave velocity and augmentation index. Linear regression model was used to evaluate the association of high-sensitivity C-reactive protein and soluble receptor for advanced glycation end products with pulse wave velocity and augmentation index. High-sensitivity C-reactive protein was analysed as a continuous variable and categories (<1, 1–3, and >3 mg/L). Results: There is no association between high-sensitivity C-reactive protein and pulse wave velocity. Augmentation index increased with high-sensitivity C-reactive protein as a continuous variable ( β = 0.328, p = 0.049) and categories ( β = 1.474, p = 0.008 for high-sensitivity C-reactive protein: 1–3 mg/L and β = 1.323, p = 0.019 for high-sensitivity C-reactive protein: >3 mg/L) after multivariable adjustment. No association was observed between augmentation index and soluble receptor for advanced glycation end products. Each unit increase in natural log–transformed soluble receptor for advanced glycation end products was associated with 0.328 m/s decrease in pulse wave velocity after multivariable adjustment ( p = 0.007). Conclusion: Elevated high-sensitivity C-reactive protein and decreased soluble receptor for advanced glycation end products are associated with augmentation index and pulse wave velocity, respectively, suggesting the potential role of systemic inflammation in the pathogenesis of central arterial stiffness in type 2 diabetes.

Download Full-text

Non-Invasive Measurement of Brachial-Ankle Pulse Wave Velocity Is Associated with Serum C-Reactive Protein but Not with .ALPHA.-Tocopherol in Japanese Middle-Aged Male Workers

Hypertension Research ◽

10.1291/hypres.27.173 ◽

2004 ◽

Vol 27 (3) ◽

pp. 173-180 ◽

Cited By ~ 28

Author(s):

Tomonori OKAMURA ◽

Yuri MORIYAMA ◽

Takashi KADOWAKI ◽

Hideyuki KANDA ◽

Hirotsugu UESHIMA

Keyword(s):

Pulse Wave Velocity ◽

Wave Velocity ◽

Pulse Wave ◽

Alpha Tocopherol ◽

C Reactive Protein ◽

Middle Aged ◽

Reactive Protein ◽

Non Invasive ◽

Invasive Measurement ◽

Middle Aged Male

Download Full-text

Effectiveness of in insulin resistance correction and the adipokines level reduction in patients with arterial hypertension in comparison with other ARBs

Russian Journal of Cardiology ◽

10.15829/1560-4071-2019-1-70-79 ◽

2019 ◽

pp. 70-79 ◽

Cited By ~ 1

Author(s):

S. V. Nedogoda ◽

E. V. Chumachek ◽

V. V. Tsoma ◽

A. S. Salasyuk ◽

V. O. Smirnova ◽

...

Keyword(s):

Insulin Resistance ◽

Pulse Wave Velocity ◽

Wave Velocity ◽

Pulse Wave ◽

Augmentation Index ◽

Model Assessment ◽

C Reactive Protein ◽

Reactive Protein ◽

Previous Therapy ◽

Azilsartan Medoxomil

Aim. To assess the possibility of azilsartan medoxomil to achieve target blood pressure (BP) (less than 130/80 mm Hg), to study angioprotective features and reduction of adipokines levels and inflammatory markers in patients with hypertension and previous therapy with other ARBs.Material and methods. In open observational study with 24 weeks follow-up were included 60 patients with previous therapy (losartan or valsartan or telmisartan).All patients underwent ambulatory BP monitoring, applanation tonometry (determination of the augmentation index and central BP), measurement of the pulse wave velocity, laboratory tests (lipid profile, uric acid, fasting glucose, Homeostasis Model Assessment, homocysteine, leptin, adiponectin, highly sensitive C-reactive protein, tumor necrosis factor alpha, interleukin-6).Results. Azilsartan provided the systolic BP (29,05%, 22,5% and 8,9%) and diastolic BP reduction 18,82%, 20,46% and 8,54% (p<0,05) in patients previously treated with losartan, valsartan or telmisartan, respectively. Central systolic BP (by 25,95%, 8,78%, 11,94%), central pulse BP (by 40%, 18,38% and 19,6%), augmentation index (by 28,87%, 20,69% and 14,29%) and pulse wave velocity (by 21,57%, 24,56% and 24,92%) were decreased (p<0,05). There were positive changes in leptin, C-reactive protein, IL-6, adiponectin levels in all patients with losartan, valsartan or telmisartan initial therapy (p<0,05).Conclusion. Azilsartan medoxomil has advantages in BP control, the arterial elasticity improving, reducing of insulin-resistance and inflammation.

Download Full-text

ASSA13-18-3 The Stratified Study of Brachial Ankle Pulse Wave Velocity and C-Reactive Protein in the Patients with Metabolic Syndrome

Heart ◽

10.1136/heartjnl-2013-303992.253 ◽

2013 ◽

Vol 99 (Suppl 1) ◽

pp. A81.4-A82

Author(s):

Zhu Wen-hua ◽

Chen Li-ying ◽

Chen Jian-hua ◽

Zhou Yue-hong

Keyword(s):

Metabolic Syndrome ◽

Pulse Wave Velocity ◽

Wave Velocity ◽

Pulse Wave ◽

C Reactive Protein ◽

Reactive Protein

Download Full-text

Impact of a Meditation Program on Pulse-Wave Velocity, C-Reactive Protein and Quality of Life

Revista Argentina de Cardiología ◽

10.7775/rac.v83.i3.4873 ◽

2015 ◽

Vol 83 (3) ◽

pp. 194-200

Keyword(s):

Quality Of Life ◽

Pulse Wave Velocity ◽

Wave Velocity ◽

Pulse Wave ◽

C Reactive Protein ◽

Reactive Protein

Download Full-text

Changes in aortic pulse wave velocity in peritoneal dialysis do not mirror changes in extracellular water measured by bioimpedance

The International Journal of Artificial Organs ◽

10.1177/0391398820931109 ◽

2020 ◽

pp. 039139882093110

Author(s):

Kamonwan Tangvoraphonkchai ◽

Andrew Davenport

Keyword(s):

Peritoneal Dialysis ◽

Pulse Wave Velocity ◽

Wave Velocity ◽

Pulse Wave ◽

Aortic Pulse Wave Velocity ◽

Confidence Limits ◽

Extracellular Water ◽

C Reactive Protein ◽

Dialysis Patients ◽

Reactive Protein

Background: Pulse wave velocity is a measurement of arterial stiffness and associated with increased cardiovascular mortality. Previous reports in peritoneal dialysis have linked increased pulse wave velocity with an expansion in extracellular water. As cardiovascular mortality is increased in peritoneal dialysis patient, we wished to determine whether changes in pulse wave velocity mirrored changes in extracellular water. Methods: We repeated aortic pulse wave velocity and bioimpedance-derived extracellular water measurements in peritoneal dialysis patients attending for assessment of peritoneal membrane function. Results: Sixty-six patients, 41 males (62.1%), mean age of 66.2 ± 13.9 years, median duration of peritoneal dialysis treatment (14.3 (3.1–31.9) months) had repeated measurement 6.4 (5.8–10.2) months apart, with no significant change in aortic pulse wave velocity (10.1 ± 3.2 to 9.9 ± 2.8 m/s). In univariate analysis, the initial aortic pulse wave velocity was associated with extracellular water (r = 0.26, p = 0.034) and serum N-terminal pro brain-type natriuretic peptide (r = 0.25, p = 0.04), and on follow-up, aortic pulse wave velocity with N-terminal pro brain-type natriuretic peptide (r = 0.31, p = 0.01). Aortic pulse wave velocity increased in 50% of patients, and these patients had greater serum C-reactive protein 3(2–10) versus 2(1–4) mg/L, and ferritin (778(444–1099) versus 585(313–811), p < 0.05), but there were no differences in either absolute or adjusted extracellular water. Both log C-reactive protein (odds ratio 4.7 (95% confidence limits 1.3–17.1), p = 0.019) and prescription of calcium channel blockers (odds ratio 4.9 (95% confidence limits 1.2–19.1), p = 0.024) were independently associated with an increase in aortic pulse wave velocity. Conclusion: We did not find an independent association between a change in aortic pulse wave velocity and extracellular water, suggesting that changes in aortic stiffness in peritoneal dialysis patients are more complex than simply following changes in extracellular water.

Download Full-text